Zoledronate to Preserve Bone Mineral Density
Name of the Trial
Why This Trial Is Important
Drugs called bisphosphonates have been shown to reduce the bone loss caused by menopause and some other medical conditions. Now doctors want to know if a bisphosphonate called zoledronate (Zometa) can help prevent bone loss in premenopausal women undergoing risk-reducing surgery to remove both ovaries.
In this trial, all women will have their bone mineral density checked prior to surgery and receive calcium and vitamin D supplements for 18 months following surgery. In addition, half of the women will be randomly assigned to receive intravenous zoledronate once every 6 months. The remaining women will be monitored without receiving additional treatment. Bone mineral density will be checked at 9 months and 18 months following surgery.
"Premenopausal women undergoing risk-reducing surgery typically are not monitored adequately for osteoporosis, but it is a very serious side effect for these women," said Dr. Alberts. "All women in this trial will benefit from very close observation, and those receiving zoledronate will be getting a drug with a record of preventing and reversing bone loss in cancer patients."
Who Can Join This Trial
Study Sites and Contact Information
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.